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Abstract
Sample size calculations based on too narrow a width, or with lower and upper confidence limits bounded by fixed
cut-off points, not only increase power-based sample sizes to ethically unacceptable levels (thus making research
practically unfeasible) but also greatly increase the costs and burdens of clinical trials. We propose an alternative
method of combining the power of a statistical test and the probability of obtaining adequate precision (the power of
the confidence interval) with an acceptable increase in power-based sample sizes.
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Correspondence
Jia and Lynn [1] describe a sample size calculation based
on an “approach that considers both statistical signifi-
cance and clinical significance.” The power-based sample
size for a statistical test is iteratively increased until there
is a satisfactorily adequate probability of obtaining an
upper confidence limit under H0 and a lower confidence
limit under H1, both bounded by fixed cut-offs, thus
making it possible to declare a definitely positive or def-
initely negative result. The authors deserve being com-
plimented on their paper, but we believe some points
should be considered further.
According to Jia and Lynn [1], “sample size needs to be
increased 4-fold when comparing normally distributed
means” and four to five times “when evaluating the log-
hazard ratio for time-to-event data”; this increase raises
substantial doubts concerning the real feasibility of phase
II/III clinical trials and, consequently, the practical useful-
ness of the method. Indeed, the sample sizes should be as
small as possible not only because “in practice, cost con-
straints force clinical trials to aim for the smallest possible
sample size” but (and more importantly) because an eth-
ical imperative exists to ensure that the number of patients
exposed to a treatment that proves to be statistically infer-
ior at the end of a controlled clinical trial is minimized.
Most statistical methods implemented in controlled
clinical trials (CCTs) have the aim of reducing the number
of enrolled patients. This aim not only meets the a priori
imperative of exposing the minimum number of patients
to the burdens of a trial [2] but also fulfills the a posteriori
imperative that as few patients as possible are adminis-
tered the treatment that proves to be inferior. These eth-
ical requirements also underlie the introduction of group
sequential designs insofar as a CCT can only be carried
out if the investigators are equipoised.
In brief, to administer patients a potentially less effect-
ive treatment only for the purpose of having a highly
precise confidence interval (CI) and/or arriving at a “def-
inite conclusion” concerning efficacy is not possible.
Jia and Lynn’s proposal of drawing “attention back to
the importance of gauging effect sizes using confidence in-
tervals” may be considered in the case of a randomized
phase IV trial aimed at assessing a drug’s effectiveness on
a continuous variable or hazard ratio as the primary out-
come. However, phase IV trials are not usually random-
ized or based on a precise estimate of the prevalence of a
rare serious adverse event.
The joint aim of obtaining power and precision with
an acceptable increase in a power-based sample size
(thus making a CCT ethically and economically feasible)
can be achieved using our proposal [3], which is based on
the first research priority of demonstrating a clinically rele-
vant difference between treatments. This approach con-
siders the precision of the effect estimate by calculating
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the standardized expected half-width (EH) of the CI ob-
tained by the power-based sample size and the probability
of obtaining standardized half-widths of sample CIs
that are less than the EH, conditional on the coverage
(P(EH|C)). In addition, the approach makes it possible
to take into account a very broad scenario of precise es-
timation by calculating various values of standardized
half-widths (Hj) and the probability of obtaining sample
standardized half-widths that are less than Hj, conditional
on the coverage (P(Hj|C)). Subsequently, by iteratively in-
creasing the starting power-based sample size, the achieve-
ment of an adequate value (at least 0.80) of the joint
probability function combining the power of the statistical
test and the power of the confidence interval (P(EH|C)) is
possible by increasing the sample size by about 20 %.
Furthermore, according to the International Conference
for Harmonization (ICH) Guidance E9 [4], “The number of
subjects in a clinical trial should always be large enough to
provide a reliable answer to the questions addressed,” and
therefore, underpowered CCTs should always be avoided.
Finally, we think the best approach to sample size calcula-
tion should simultaneously fulfill the two research require-
ments of having an adequate probability of demonstrating a
difference (power of the statistical test) and being capable
of estimating it as precisely as possible (power of the CI).
Therefore, we believe it is sensible to start from the EH
derived from the power-based sample sizes, which should
be considered the precision threshold given the foreseen
difference under H1.
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